MILLIPLEX^® Human Kidney Injury Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 7 analytes in human serum or plasma samples.Analytes included: α-1-Microglobulin, Albumin, Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features:
Measures 7 key biomarkers of kidney injury in human urine samples

Includes α-1-Microglobulin, Albumin, Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, and Osteopontin (OPN)

Magnetic bead-based format for enhanced precision and simplified washing

Utilizes Luminex^® xMAP^® technology for multiplexing and high-throughput analysis

Validated for human urine with recommended sample dilution of 1:100

Assay sensitivity ranges from 0.015 to 5.359 ng/mL depending on the analyte

Standard curve ranges from 0.01 to 5,000 ng/mL across analytes

Intra-assay CV < 10%, inter-assay CV < 20%

Benefits:

Enables early and specific detection of kidney injury before traditional markers like BUN and serum creatinine

Provides insight into organ-specific damage and mechanisms of nephrotoxicity

Conserves sample volume by analyzing multiple biomarkers in a single run

Supports drug safety and toxicity research with high analytical performance

Reduces assay variability and improves reproducibility across studies

Compatible with both manual and automated workflows for flexible lab integration

Albumin, Beta-2 Microglobulin, Clusterin, Cystatin C, and Lipocalin-2/NGAL are important biomarkers for evaluating kidney function, tubular integrity, and early signs of renal injury. These analytes help detect glomerular filtration changes, proteinuria, and inflammation, making them valuable for monitoring acute and chronic kidney conditions. Their combined assessment supports sensitive and specific evaluation of renal health.